World Renowned ALS Expert From Harvard Medical School and Mass. General Hospital,...

World Renowned ALS Expert From Harvard Medical School and Mass. General Hospital, Dr. Robert H. Brown Jr., Joins BrainStorm Cell Therapeutics Scientific Advisory Board

NEW YORK & PETACH TIKVAH, Israel--(Business Wire)--
Brainstorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading
developer of adult stem cell technologies and therapeutics, announced
today that world renowned ALS medical expert, Dr. Robert H. Brown,
Jr., MD, PhD from Harvard Medical School and Massachusetts General
Hospital (MGH), has joined the Company's Scientific Advisory Board
(SAB) to assist in preparations for ALS clinical trials.

Brainstorm Cell Therapeutics is dedicated to the research and
development of innovative adult stem-cell based therapeutic treatments
for ALS and Parkinson's diseases, based on cells secreting
Neurotrophic Factors. The Company aims to receive approval to begin
clinical trials in Israel in 2009. In the last months, Dr. Brown
visited BrainStorm's offices, Laboratories and the Animal research
facility, and after punctilious due diligence decided to join the
company.

Dr. Robert H. Brown, Jr., a Professor of Neurology at Harvard
Medical School and a neurologist at MGH, is recognized for his
pioneering work on the genetics of the motor neuron disease
amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's
disease. In 1993, Brown and his associates were the first to identify
a gene that causes familial ALS cases, and which has been the basis
for the development of the most widely studied animal model of ALS.
Dr. Brown has subsequently investigated other genetic variants that
cause ALS and strategies for ALS therapy.

In 1983, Dr. Brown founded the Cecil B. Day Laboratory for
Neuromuscular Research at Massachusetts General Hospital, an
internationally renowned center for research and advancement of
clinical care in this field. Dr. Brown's research has been published
in the most distinguished scientific journals, including Science and
Nature. His work has garnered many accolades, including his acceptance
into the Institute of Medicine and the American Neurological
Association. In 2007, Brown received the Robert Wartenberg Lecture
Award from the American Academy of Neurology for excellence in
clinically relevant research. In fall 2008, he will move his
laboratories to the University of Massachusetts Medical School where
he will become the Chair of Neurology.

Chaim Lebovits, Brainstorm's President commented, "We have the
honor to welcome ALS expert Dr. Brown to Brainstorm. Dr. Brown will
add to the Company's expertise with his 30 years of professional
experience in ALS research and care. Dr. Brown's passion for treating
ALS patients and his drive to improve their lives and prognosis,
coupled with his academic and clinical brilliance and experience will
be critically valuable as, with G-d's help, Brainstorm moves forward
towards clinical trials."

Dr. Brown added: "I am delighted to be able to help Brainstorm
Cell Therapeutics develop protocols for testing its lead products as
ALS therapies. It will be a pleasure to work closely with the
outstanding scientists and clinicians at Brainstorm."

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company
developing adult stem cell therapeutic products, derived from
autologous (self) bone marrow cells, for the treatment of
neurodegenerative diseases. The NurOwn(TM) patent pending technology
is based on discoveries made by the scientific team led by prominent
neurologist Professor Eldad Melamed, Head of Neurology at Rabin
Medical Center, and expert cell biologist Dr. Daniel Offen, Head of
the Neuroscience Laboratory at the Felsenstein Medical Research Center
of Tel-Aviv University. The technology allows for the differentiation
of bone marrow-derived stem cells into functional neurons and
astrocytes, as demonstrated in animal models. The Company holds rights
to develop and commercialize the technology through an exclusive,
worldwide licensing agreement with Ramot at Tel Aviv University Ltd.,
the technology transfer company of Tel-Aviv University. The Company's
initial focus is on Parkinson ALS and Spinal Cord Injury, although its
technology has promise for treating several others diseases including
MS, Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve risks
and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s
actual results to differ materially from those stated or implied by
such forward-looking statements, including BrainStorm's ability to
complete its equity financing transactions previously disclosed. The
potential risks and uncertainties include, among others, risks
associated with BrainStorm Cell Therapeutics Inc.'s limited operating
history, history of losses and expectation to incur losses for the
foreseeable future; dependence on its license to Ramot's technology;
ability, together with its licensor, to adequately protect the
NurOwn(tm) technology; dependence on key executives and on its
scientific consultants; ability to identify, negotiate and
successfully implement strategic partnering relationships; ability to
complete clinical trials successfully and to obtain required
regulatory approvals; competition with companies, some of which have
greater resources and experience in developing and obtaining
regulatory approval for treatments in BrainStorm Cell Therapeutics
Inc.'s market; the limited public trading market for BrainStorm Cell
Therapeutics Inc.'s stock which may never develop into an active
market; and other factors detailed in BrainStorm Cell Therapeutics
Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-Q,
current reports on Form 8-K and other filings with the Securities and
Exchange Commission available at http://www.sec.gov/ or by request to
the Company. The Company does not undertake any obligation to update
forward-looking statements made by us.

BrainStorm Cell Therapeutics Inc.
Chaim Levinson, +972-545-633683
Clevinson@brainstorm-cell.com

Copyright Business Wire 2008